Liver/Biliary Disorders News

Using clinical bloodwork like FIB-4 and elastography technology in combination, Researchers at the International Liver congress proposed they could better identify patients with advanced fibrosis using clinical bloodwork like FIB-4 and elastography technology in combination.

A high maternal pre-pregnancy BMI increases the risk of offspring developing non-alcoholic fatty liver disease, according to findings presented at the 2021 International Liver Congress

A novel GaINAc-conjugated RNAi therapeutic meant to replicate the protective nature of a mutation showed promising efficacy in a proof-of-concept study in the first five patients treated with the medication.

Resmetirom rapidly reduced hepatic fat, fibrosis and biomarkers among patients with nonalcoholic steatohepatitis, according to a presentation at the International Liver Congress.

A novel liver dialysis device that rids the body of dysfunctional albumin and replaces it with fresh albumin significantly improved survival rates among patients with acute-on-chronic liver failure, according to a presenter at The International Liver Congress.

Recurrent autoimmune hepatitis after liver transplantation affected graft and overall survival, according to a presentation at the International Liver Congress.

Treatment with hepatic arterial infusion chemotherapy in combination with sintilimab allowed for surgical resection and produced survival rates similar to lesser advanced hepatocellular carcinoma, according to a presenter at The International Liver Congress.

Researchers saw higher reduction in steatosis and body weight with the low-carb high-fat and 5:2 diets compared with the standard of care in patients with nonalcoholic fatty liver disease, according to a presentation at the International Liver Congress.

Patients with metabolic-associated fatty liver disease or higher transaminases who were then diagnosed with COVID-19 were more likely to die, according to a presenter at the International Liver Congress

Monotherapy with bulevirtide among patients with compensated hepatitis delta was safe and well tolerated, according to a presentation at the International Liver Congress.